Coronavirus Disease 2019 and the Myocardium

Imagem de Miniatura
Arquivos
art_FIGUEIREDO NETO_Coronavirus_Disease_2019_and_the_Myocardium_2020.PDF (553.29 KB)
Citações na Scopus
15
Tipo de produção
article
Data de publicação
2020
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ARQUIVOS BRASILEIROS CARDIOLOGIA
Autores
FIGUEIREDO NETO, Jose Albuquerque de
MOURA, Lidia Zytinski
FIGUEIREDO, Andre Melo e Silva de
FIGUEIREDO, Viviane Melo e Silva de
MOURILHE-ROCHA, Ricardo
MESQUITA, Evandro Tinoco
Citação
ARQUIVOS BRASILEIROS DE CARDIOLOGIA, v.114, n.6, p.1051-1057, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Infection with the coronavirus known as COVID-19 has promoted growing interest on the part of cardiologists, emergency care specialists, intensive care specialists, and researchers, due to the study of myocardial involvement based on different clinical forms resulting from immunoinflammatory and neurohumoral demodulation. Myocardial involvement may be minimal and identifiable only by electrocardiographic changes, mainly increased cardiac troponins, or, on the other side of the spectrum, by forms of fulminant myocarditis and takotsubo syndrome. The description of probable acute myocarditis has been widely supported by the observation of increased troponin in association with dysfunction. Classical definition of myocarditis, supported by endomyocardial biopsy of inflammatory infiltrate, is rare; it has been observed in only one case report to date, and the virus has not been identified inside cardiomyocytes. Thus, the phenomenon that has been documented is acute myocardial injury, making it necessary to rule our obstructive coronary disease based on increased markers of myocardial necrosis, whether or not they are associated with ventricular dysfunction, likely associated with cytokine storms and other factors that may synergistically promote myocardial injury, such as sympathetic hyperactivation, hypoxemia, arterial hypotension, and microvascular thrombotic phenomena. Systemic inflammatory and myocardial phenomena following viral infection have been well documented, and they may progress to cardiac remodeling and myocardial dysfunction. Cardiac monitoring of these patients is, therefore, important in order to monitor the development of the phenotype of dilated myocardiopathy.
Palavras-chave
Myocardium/injuries, Troponin, Inflammatory Diseases, Myocarditis, Takotsubo Syndrome, Biomarkers, Coronavirus, COVID-19, Pandemics, Cardiomyopathy, Dilated, Thrombotic Microangiopathies
URI
https://observatorio.fm.usp.br/handle/OPI/37224
Referências
  1. Arachchillage DRJ, 2020, J THROMB HAEMOST, V18, P1233, DOI [10.1111/jth.14820, 10.1111/jth.14768]
  2. Atri D, 2020, JACC BASIC TRANSL SC
  3. BALLIGAND JL, 1993, J CLIN INVEST, V91, P2314, DOI 10.1172/JCI116461
  4. Bangalore S, 2020, N ENGL J MED
  5. Chapman AR, 2018, CIRCULATION, V137, P1236, DOI 10.1161/CIRCULATIONAHA.117.031806
  6. Chen L, 2020, CARDIOVASC RES, V116, P1097, DOI 10.1093/cvr/cvaa078
  7. Corrales-Medina VF, 2015, JAMA-J AM MED ASSOC, V313, P264, DOI 10.1001/jama.2014.18229
  8. Costa IBSS, 2020, ARQ BRAS CARDIOL
  9. Cox D, 2011, J THROMB HAEMOST, V9, P1097, DOI 10.1111/j.1538-7836.2011.04264.x
  10. Ding YQ, 2004, J PATHOL, V203, P622, DOI 10.1002/path.1560
  11. Ding YQ, 2003, J PATHOL, V200, P282, DOI 10.1002/path.1440
  12. Fung G, 2016, CIRC RES, V118, P496, DOI 10.1161/CIRCRESAHA.115.306573
  13. Green J, 2002, THROMB HAEMOSTASIS, V87, P218
  14. Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
  15. Guillevin Loic, 2004, Clin Dev Immunol, V11, P227, DOI 10.1080/17402520400001744
  16. Guo T, 2020, JAMA CARDIOL
  17. Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
  18. Hobai IA, 2015, SHOCK, V43, P3, DOI 10.1097/SHK.0000000000000261
  19. Hoffmann M, 2020, CELL, V181, P271, DOI [10.1080/10255842.2020.1789606, 10.1016/j.cell.2020.02.052]
  20. Hu H., 2020, EUR HEART J
  21. Imai Y, 2005, NATURE, V436, P112, DOI 10.1038/nature03712
  22. Inciardi RM, 2020, JAMA CARDIOL
  23. Kumar A, 1996, J EXP MED, V183, P949, DOI 10.1084/jem.183.3.949
  24. Levi M, 2004, CIRCULATION, V109, P2698, DOI 10.1161/01.CIR.0000131660.51520.9A
  25. Libby P, 2020, JACC BASIC TRANSL SC, V5, P537
  26. Libby P, 2018, J AM COLL CARDIOL, V72, P2071, DOI 10.1016/j.jacc.2018.08.1043
  27. Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
  28. de Chazal HM, 2018, J AM COLL CARDIOL, V72, P1955, DOI 10.1016/j.jacc.2018.07.072
  29. Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
  30. Meyer P, 2020, EUR HEART J, V41, P1860, DOI 10.1093/eurheartj/ehaa306
  31. Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08
  32. NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823
  33. Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433
  34. Oudit GY, 2009, EUR J CLIN INVEST, V39, P618, DOI 10.1111/j.1365-2362.2009.02153.x
  35. Pagnoux C, 2006, CLIN EXP RHEUMATOL, V24, pS71
  36. Pathan N, 2004, LANCET, V363, P203, DOI 10.1016/S0140-6736(03)15326-3
  37. Qin C, 2020, CLIN INFECT DIS, V248
  38. Sala S, 2020, EUR HEART J, V41, P1861, DOI 10.1093/eurheartj/ehaa286
  39. Sarkisian L, 2016, AM J MED, V129, P506, DOI 10.1016/j.amjmed.2015.12.009
  40. Shi S, 2020, JAMA CARDIOL, DOI [10.1001/jamacardio.2020, DOI 10.1001/JAMACARDIO.2020MAR25]
  41. Simmons J, 2015, CURR OPIN ANESTHESIO, V28, P227, DOI 10.1097/ACO.0000000000000163
  42. Stanzani G, 2019, BBA-MOL BASIS DIS, V1865, P759, DOI 10.1016/j.bbadis.2018.10.011
  43. Tavazzi G, 2020, EUR J HEART FAIL, V22, P911, DOI 10.1002/ejhf.1828
  44. Thygesen K, 2018, J AM COLL CARDIOL, V72, P2231, DOI 10.1016/j.jacc.2018.08.1038
  45. Turner AJ, 2004, TRENDS PHARMACOL SCI, V25, P291, DOI 10.1016/j.tips.2004.04.001
  46. Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206
  47. Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X
  48. van de Veerdonk Frank L, 2011, Trends Immunol, V32, P110, DOI 10.1016/j.it.2011.01.003
  49. Violi F, 2014, J THROMB HAEMOST, V12, P1391, DOI 10.1111/jth.12646
  50. Xu XT, 2020, SCI CHINA LIFE SCI, V63, P457, DOI 10.1007/s11427-020-1637-5
  51. Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
  52. Yao XH, 2020, CHINESE J PATHOL, V49, P411, DOI 10.3760/CMA.J.CN112151-20200312-00193
  53. Zhao Y., 2020, BIORXIV
  54. Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3
  55. Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - ODS/03